Issue 126

LSD

The 80th birthday of LSD

Regulatory reform to decriminalise the use of psilocybin is taking place in a dozen states across the US, and is no longer confined to the West Coast – with lawmakers proposing bills in New York, Connecticut and Virginia.

On 19 April 1943, eighty years ago today, Albert Hofmann intentionally consumed LSD, marking the first recorded experience with the psychedelic medicine.

Hofmann synthesised LSD-25 in 1936 while researching stimulants and ergot’s impact on the cardiovascular system. It wasn’t until seven years later, however, that he became aware of its psychoactive properties – through accidental exposure.

When Hofmann purposely drank 250μg of LSD, diluted in water, he soon found himself intoxicated and asked his assistant to escort him home.

The hallucinations intensified on the bicycle ride from the laboratory, with the event later eternalised within the counterculture community as ‘bicycle day’.

READ MORE

OREGON LICENSES FIRST PSILOCYBIN FACILITATORS

The Oregon Health Authority has approved three individuals to provide psilocybin services.

Read More

AWAKN PARTNERS WITH THE UNIVERSITY OF EXETER

Awakn will now contribute just £800,000 to its Phase III study into alcohol use disorder.

Read More

BUSINESS AND INVESTMENT

Numinus Wellness reports Q2 2023 financial results. Revenues grew 581% year-over-year, to reach C$5.4 million.

Treating long COVID with psychedelic medicines. Reports indicates they may treat persistent symptoms of COVID-19.

Cybin launches cost-free facilitator training programme. The course helps improve access to psychological support.

The US could soon approve MDMA-assisted therapy. MAPS hopes to submit a New Drug Application by October.

Bicycle Day 2023. Looking back at the synthesis, adoption and scheduling of LSD.

The New Health Club partners with Dimensions. The collaboration hopes to provide psychedelic retreats in Europe.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Second release tickets on sale for £329 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

Appraising placebo responses in psychiatry. In clinical trails and neuroscience research, large responses are seen following a placebo.

Neurocognitive effects of subanesthetic ketamine infusions. Four ketamine infusions led to improvements in cognition up to five weeks later.

REGULATION AND LEGISLATION

Senators in Washington approve psilocybin pilot programme. A bill is now with the state’s governor for approval.

Governor in New Mexico vetoes drug decriminalisation bill. The lawmaker said imprisonment is an important deterrent.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT

ARTICLES OF INTEREST

The trouble treating adult ADHD. A shortage in Adderral exposes a gap in effective treatments.

NHS fails to treat 250,000 children with mental health conditions. One-third of referrals are denied treatment.

Psychedelic Health is a media partner for Breaking Convention, which takes place at the University of Exeter.

Use the code ‘PHBC10‘ for a 10% discount and if you would like to meet with Psychedelic Health, please email stephanie@psych.global.

TICKET REGISTRATION